Tirzepatide

Strong Evidence

TL;DR

• Tirzepatide is a prescription medicine, not a research-vendor peptide.
• It activates both GIP and GLP-1 receptors and has strong clinical-trial evidence for weight reduction in adults with obesity.
• FDA-approved indications include type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity.
• It carries important safety warnings and should only be used under qualified medical supervision.

What It Is

Tirzepatide is a synthetic peptide-based incretin therapy that activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In clinical use, it is positioned differently from research peptides such as BPC-157 or TB-500: tirzepatide is an approved prescription drug for defined indications and should be evaluated through regulated medical channels.

Mechanistically, tirzepatide affects appetite, food intake, glycemic control, and weight through incretin signaling. The dual-receptor design is part of why it is often discussed separately from older GLP-1-only therapies such as semaglutide.

Evidence Summary

Study	Year	N	Outcome	Limitations
SURMOUNT-1 obesity trial	2022	2539	Once-weekly tirzepatide produced mean weight reductions of about 15.0%, 19.5%, and 20.9% at 5 mg, 10 mg, and 15 mg at 72 weeks, versus 3.1% with placebo.	Excluded participants with diabetes; sponsor-funded trial.
FDA OSA approval review	2024	469	FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity based on two randomized studies showing significant AHI reduction.	OSA benefit is described as likely related to weight reduction.

Evidence level: Strong for approved metabolic and weight-management indications when used as prescribed.

Legal Status by Jurisdiction

US (FDA). Tirzepatide is FDA-approved as a prescription medicine under brand names including Mounjaro and Zepbound. PeptideUnicorn does not route care or sell tirzepatide.

UK (MHRA). Tirzepatide is handled through prescription medicine pathways. Availability, indication, and reimbursement depend on local authorization and clinical criteria.

AU (TGA). Tirzepatide should be treated as a prescription medicine subject to Australian therapeutic goods rules and clinician assessment.

WADA. Athletes should not infer permissibility from prescription status. Anti-doping obligations and therapeutic-use exemption rules can differ from ordinary prescribing rules.

Typical Use Protocols

For tirzepatide, “protocol” means the approved prescribing pathway and product label, not community dosing. Dose selection, escalation, contraindications, monitoring, and discontinuation decisions belong with a qualified clinician.

Side Effects and Contraindications

The FDA describes common Zepbound side effects including nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and reflux. The drug also carries warnings involving thyroid C-cell tumors observed in rats, pancreatitis, gallbladder problems, hypoglycemia risk in some combinations, kidney injury, diabetic retinopathy in patients with type 2 diabetes, suicidal behavior or thinking, and pulmonary aspiration risk around anesthesia.

How to Source It

Tirzepatide belongs in the regulated prescription path. PeptideUnicorn does not recommend buying tirzepatide through research-vendor or gray-market channels.

Change Log

• 2026-05-27: Initial PeptideUnicorn profile published.

References

References

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
2. FDA. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024.
3. ClinicalTrials.gov. SURMOUNT-1, tirzepatide in participants with obesity or overweight.

Continue Reading

Readers also explore

All peptides →

Metabolic

Semaglutide

GLP-1 Receptor Agonist

Type 2 diabetes · Chronic weight management · Cardiovascular risk reduction in selected patients

Open profile

Metabolic

Retatrutide

Triple GIP, GLP-1, and Glucagon Receptor Agonist

Obesity research · Metabolic disease research · Liver disease research

Open profile